We have recently added 6 new cancer clinical trials into our 3CTN Portfolio:
| Trial Short Title |
Disease Site |
Complexity Rating |
Registration ID |
| (CCTG) IND.241B / Sub-Study B |
Breast |
High |
NCT05601440 (B) |
| (CCTG) IND.241C / Sub-Study C |
Breast |
High |
NCT05601440 (C) |
| (CCTG) MA.41 / IJB-EBC-Decrescendo-2020 / BIG 19-02* |
Breast |
Standard |
NCT04675827 |
| (CCTG) EN.10 / RAINBO Blue / TAPER |
Gynecological |
Standard |
NCT05640999 |
| (UHN) OZM-109* |
Hematology |
High |
NCT04566887 |
| (UHN) CHAMP-F |
Other |
Low |
NCT05499975 |
|
|
Featured Trials*
(CCTG) MA.41 / IJB-EBC-Decrescendo-2020 / BIG 19-02: De-Escalation of Adjuvant Chemotherapy in HER2-positive, Estrogen Receptor-negative, Node-negative Early Breast Cancer Patients Who Achieved Pathological Complete Response After Neoadjuvant Chemotherapy and Dual HER2 Blockade
Canadian Sponsor: Canadian Cancer Trials Group (CCTG)
NCT#: NCT04675827
Summary:
DECRESCENDO is a multicentre, open-label, dual-phase single-arm phase II study evaluating de-escalation of adjuvant chemotherapy in HER-2 positive, estrogen receptor-negative, node-negative, early breast cancer patients who achieved pathological complete response after neoadjuvant chemotherapy and dual HER-2 blockade.
Canadian Trial Status: Open to recruitment
Target enrollment: 1065
Open to additional sites: Limited to invited centres
Canadian Contact: Lois Shepherd, Canadian Cancer Trials Group
Email: lshepherd@ctg.queensu.ca
Phone: 613-533-6430
(UHN) OZM-109: A Phase II Study of Acalabrutinib in Combination With R-CHOP Chemotherapy in Previously Untreated Mantle Cell Lymphoma
Canadian Sponsor: University Health Network (UHN)
NCT#: NCT04566887
Summary:
This is a multicenter, open-label, non-randomized, phase II clinical trial being conducted in Canada. The purpose of the study is to determine the remission rate of acalabrutinib in combination with R-CHOP chemotherapy in patients with previously untreated mantle cell lymphoma prior to autologous stem cell transplantation (ASCT). All patients will receive six cycles of R-CHOP chemotherapy together with continuous acalabrutinib at the standard dose twice per day orally. All patients will then undergo response assessment with CT scan, PET/CT scan, and bone marrow biopsy. Responding patients will proceed with stem cell mobilization, apheresis, and processing. Following ASCT, patients will receive standard maintenance rituximab every 3 months for 2 years.
Canadian Trial Status: Open to recruitment
Target enrollment: 54
Open to additional sites: Yes
Canadian Contact: John Kuruvilla, MD, UHN, Toronto
Email: John.Kuruvilla@uhn.ca
Phone: 416-946-2821
|
|
Promote Your Trials!
Do you want to promote a trial in an upcoming Portfolio Watch issue or for inclusion in the next impACCT Virtual Rounds session?
Please email info@3ctn.ca to have your nominated trial included! |
|
|
New Release! Y9Q3 Performance Report
View the Performance Report to see Y9Q3 recruitment metrics, trial activity, and a full list of trials added to the 3CTN Portfolio during Y9Q3.
 
You can see all previous Performance Reports plus 3CTN's interactive reports here.
|
|
Rewatch! impACCT Virtual Rounds Winter Session
3CTN’s impACCT Virtual Rounds Winter Session was held on February 7, 2023 and featured two Portfolio trials, (CCTG) PAC.4 /ECOG-ACRIN EA2185 and (UHN) 21-5126) Peer Navigation pRCT. This session was co-facilitated by Patient Representatives Kathy Smith and Bill Richardson, who provided their unique patient perspectives and valuable insight into the discussions. Their support was instrumental in making the Winter Session a success.
Please save the date for the upcoming impACCT Virtual Rounds Spring Session on May 16, 2023.
|
|
Other Upcoming Dates:
- May 15, 2023: Year 9, Q4 (January– March 2023) reports due
- May 16, 2023: impACCT Virtual Rounds Spring Session
|
|
|
|
